in

PathAI and Roche workforce as much as push adoption of digital pathology tech

PathAI, maker of AI-enabled pathology merchandise, introduced Friday it was partnering with pharma and diagnostics big Roche.

The strategic partnership will permit PathAI to develop and distribute its AI pathology tech by way of Roche’s uPath enterprise software, a workflow platform for labs.  

The collaboration will start with distributing PathAI’s research-use-only algorithms by way of the cloud model of Roche’s uPath software program, with a deal with immuno-oncology for the remedy of a number of kinds of cancers.

WHY IT MATTERS

PathAI is pitching the partnership as a solution to push adoption of AI-powered digital pathology tech in labs, which it argues has been sluggish as a result of the digital pathology business is fragmented throughout completely different software program, {hardware} and algorithm suppliers. 

“This collaboration brings together all of the components required to deliver and commercialize a differentiated AI-based digital pathology medical device including assay, scanner, image management system and image analysis algorithms. We believe this collaboration will unlock the potential for digital pathology in the CDx [companion diagnostic] setting, offering a differentiated service to biopharma sponsors and ultimately new opportunities to improve patient outcomes,” Dr. Andy Beck, CEO of PathAI, stated in a press release.

THE LARGER TREND

In July, PathAI added lab testing providers to its portfolio with the acquisition of Poplar Healthcare Management. 

The deal got here months after the corporate introduced it had scored $165 million in Series C funding, bringing its whole raised to $255 million. 

Meanwhile, Roche has inked different offers this yr, together with one with pharma big Eli Lilly to combine with its Tempo Pen and Tempo Smart Button. It’s additionally working with Diabeloop for automated insulin supply and Novo Nordisk to combine with its diabetes administration app mySugr.

Other corporations within the digital pathology house embrace Proscia, which in March partnered with AI oncology diagnostic platform Ibex Medical Analytics; Paige, which acquired De Novo clearance from the Food and Drug Administration final month for its AI software program that helps detect prostate most cancers; and well being tech big Royal Philips, which right this moment introduced a brand new digital pathology suite known as IntelliSite. 

Pakistan Cricket Unveils The Jersey For T20 World Cup, Mentions India 2021 Instead Of UAE 2021

Supercomputers Mimic Brain Activity, Hunt for COVID Treatments